FSD Pharma Inc. Files 6-K with Corporate Updates

Ticker: QNTM · Form: 6-K · Filed: Jun 28, 2024 · CIK: 1771885

Fsd Pharma Inc. 6-K Filing Summary
FieldDetail
CompanyFsd Pharma Inc. (QNTM)
Form Type6-K
Filed DateJun 28, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, filing

TL;DR

FSD Pharma filed a 6-K on June 28th with corporate updates, including a press release. Check for details.

AI Summary

FSD Pharma Inc. filed a Form 6-K on June 28, 2024, to report on corporate updates. The filing includes a press release (Exhibit 99.1) detailing these updates, though the specific content of the press release is not detailed in the provided text. The company is incorporated in Canada and its principal executive office is located in Toronto, Ontario.

Why It Matters

This filing indicates that FSD Pharma Inc. is providing material information to the public, which could affect investor decisions regarding the company's stock.

Risk Assessment

Risk Level: medium — Form 6-K filings often contain updates that can be material, but without the specific content of the press release, the immediate impact and associated risk are uncertain.

Key Players & Entities

  • FSD Pharma Inc. (company) — Registrant
  • Nathan Coyle (person) — Chief Financial Officer
  • June 28, 2024 (date) — Filing date

FAQ

What specific corporate updates are detailed in Exhibit 99.1?

The provided text states that Exhibit 99.1 is a Press Release providing 'Corporate U' (presumably 'Updates'), but the specific content of the updates is not detailed in the 6-K filing itself.

What is FSD Pharma Inc.'s principal executive office address?

FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.

Who signed the Form 6-K on behalf of FSD Pharma Inc.?

The Form 6-K was signed by Nathan Coyle, Chief Financial Officer, on behalf of FSD Pharma Inc.

What is the SEC file number for FSD Pharma Inc.?

The SEC file number for FSD Pharma Inc. is 001-39152.

Does FSD Pharma Inc. file annual reports under Form 20-F or 40-F?

FSD Pharma Inc. indicated that it files annual reports under Form 20-F.

Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-06-28 17:01:24

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: June 28, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.